Early Intervention to Prevent Development of PTSD in Burn Survivors and Their Caregivers
2026年6月14日 更新者：University of Southern California
The purpose of this clinical trial is to adapt and test a brief patient-caregiver early intervention designed to reduce posttraumatic stress symptoms in hospitalized burn patients and their caregivers.
This intervention is a brief, 4-session cognitive-behavioral intervention designed for burn patients and their loved one to complete together, during and after hospitalization.
The intervention targets relational communication and functioning through reduction of invalidating, negative statements and avoidant coping by teaching patients and their loved ones to engage in adaptive natural disclosures, supportive responses, and approach coping after the burn trauma.
The intervention uses evidence-based psychotherapy techniques, including psychoeducation, motivational interviewing, and skills coaching.
The clinical trial will occur in two sequential phases.
In the first phase of the study (case series), the intervention will be provided to two burn patient-caregiver dyads (four adults) to pilot test the intervention, seek patient and provider feedback, and refine the intervention.
All four adults will receive the intervention.
In the second phase of the study, the randomized controlled trial (RCT) phase, investigators will enroll 20 more burn patient-caregiver dyads (40 more adults) who will be randomly assigned (like the flip of a coin) at the dyad level to receive the intervention or a burn survivor-only minimally enhanced usual care psychoeducation control condition (mEUC).
The goals of the RCT phase are to study whether the intervention is acceptable to patients, feasible to conduct, and whether the intervention improves burn survivor-caregiver healthy relationship communication about difficult events and treatment outcomes compared to mEUC.
調査の概要
状態
まだ募集していません
条件
研究の種類
介入
入学 (推定)
44
段階
- 適用できない
連絡先と場所
このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。
研究連絡先
- 名前：Sarah Stoycos, PhD
- 電話番号：323-409-7621
- メール：sarah.stoycos@med.usc.edu
研究場所
-
-
California
-
Los Angeles、California、アメリカ、90033
- University of Southern California, Keck School of Medicine & Los Angeles General Medical Center
-
コンタクト：
- Sarah Stoycos, PhD
- 電話番号：323-409-7621
- メール：sarah.stoycos@med.usc.edu
-
-
参加基準
研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。
適格基準
就学可能な年齢
- 大人
- 高齢者
健康ボランティアの受け入れ
はい
説明
Inclusion Criteria:
- Alert, oriented, & not withdrawing from substance at time of screening
- Can read and write in English
- Hospitalized within 10 days of burn injury
- Anticipated discharge <=4 weeks
- Have an email, mailing address, and at least 1 smart device for telehealth sessions
- PTSD risk score of 2 or greater (patient-only)
- Willing to attend therapy sessions with a loved one
Exclusion Criteria:
- Currently incarcerated or in police custody
- > 10 days post-burn
- Lifetime diagnosis of primary psychosis or intellectual disability
- Ongoing reported domestic violence in the dyad
- Unstable bipolar disorder, severe substance use disorder, or acute suicidality with imminent intent that does not remit within 10 days of burn-injury
- Inflammation Confounds (patient-only) of BMI > 40, metabolic syndrome, admission A1C of >= 6.5%
- Currently receiving couples therapy
研究計画
このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。
研究はどのように設計されていますか？
デザインの詳細
- 主な目的：防止
- 割り当て：ランダム化
- 介入モデル：並列代入
- マスキング：独身
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的：Promotion of Emotional Disclosure for Burns (PoED-B)
Participants randomized into this arm will receive Promotion of Emotional Disclosure for Burns (PoED-B), a cognitive behavioral therapy intervention designed for burn survivors and a loved one of their choosing to complete together.
The standard treatment length will be 4 sessions, however participants and providers may agree to additional sessions as warranted.
|
PoED-B is a dyadic treatment where both patient and identified informal caregiver participate.
PoED-B targets reducing disclosure-constraining behaviors (e.g., invalidating, negative statements) using psychoeducation, motivational interviewing, and skills training.
The goal is to encourage the patient-caregiver dyad to engage in natural disclosures, supportive responses, and approach coping after the burn trauma to facilitate emotional processing.
It is four sessions long.
Delivery format takes into account stakeholder feedback, considering overall burden during acute hospitalization and the transition to outpatient care.
Sessions one and two are 30 minutes and one week apart.
Sessions three and four are 50 minutes long and two weeks apart.
Session one must occur during hospitalization.
Sessions 2-4 can be completed via video/telehealth if the patient is discharged during the treatment course.
|
|
アクティブコンパレータ：minimally Enhanced Usual Care control (mEUC)
Participants randomized into this arm will receive a minimally enhanced version of usual burn care.
This will include one, 30-minute supportive therapy session focused on psychoeducation about the potential psychological impact of burn injury and hospitalization and referral to outpatient resources, if wanted.
|
mEUC is an individually-administered psychoeducation control for burn patients modeled after minimally enhanced care in acute care surgery units.
In one 30-minute session, the therapist reviews with the participant a standardized psychoeducation handout on common psychological reactions after burn injury, giving them time to ask questions or express concerns within a supportive therapy framework.
Then, the participant is given the handout, which also includes self-help skills.
After study completion, participants will be given referrals for outpatient mental health services.
|
この研究は何を測定していますか？
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Social Constraints Scale
時間枠：Before treatment, immediately after ending treatment, 6-week follow-up
|
The Social Constraints Scale is a self-report scale administered to both the patient and caregiver.
It is designed to assess perceptions of negative reactions to trauma-disclosures.
The scale contains 15 items, and each item is scored on a four-point scale ranging from 1 (never) to 4 (often) with total scores ranging from 15 to 60.
A higher score indicates a higher frequency of experiencing social constraints.
|
Before treatment, immediately after ending treatment, 6-week follow-up
|
|
Feasibility of Recruitment
時間枠：baseline
|
Proportion of participants who agree to participate from the total number of those that are eligible and approached.
|
baseline
|
|
Feasibility of Data Collection
時間枠：From enrollment to the end of study assessments at 6-weeks posttreament
|
Proportion of participants who completed each and all assessment timepoints
|
From enrollment to the end of study assessments at 6-weeks posttreament
|
|
Acceptability: Satisfaction with Treatment
時間枠：Immediately after ending treatment
|
Client Satisfaction Questionnaire (CSQ) - Self-Report - The CSQ has 8 items assessing client satisfaction with the treatment they have received.
Total scores range from 8-32; higher scores indicate greater client satisfaction/treatment acceptability.
This measure will be completed by both patients and their loved ones.
|
Immediately after ending treatment
|
|
Acceptabilitly: Retention
時間枠：Immediately after ending treatment
|
Proportion of enrolled dyads who completed at least 3 out of 4 PoED sessions.
|
Immediately after ending treatment
|
|
Acceptability: Global Improvement Rating
時間枠：Immediately after ending treatment
|
Proportion of participants who report overall improvement on the Global Rating of Change Scale
|
Immediately after ending treatment
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
PTSD Checklist for DSM-5 (PCL-5)
時間枠：Pretreatment, Immediately after ending treatment, 6-week follow-up
|
The PTSD Checklist for DSM-5 is a 20 item self-report measure assessing PTSD symptom severity.
Total scores range from 0-80 with higher scores indicating more severe PTSD symptoms.
|
Pretreatment, Immediately after ending treatment, 6-week follow-up
|
|
Clinician-Administered PTSD Scale for DSM-5 (CAPS-5)
時間枠：Immediately after ending treatment, 6-week follow-up
|
The Clinician-Administered PTSD Scale for DSM-5 is a structured interview measure of PTSD symptom severity (frequency and intensity) in the past month.
Scores can range from 0-80, with higher scores indicating worse symptom severity.
Only burn patients will complete this measure, not caregivers.
|
Immediately after ending treatment, 6-week follow-up
|
|
Hospital Anxiety and Depression Scale (HADS)
時間枠：Pretreatment, immediately after ending treatment, 6-week follow-up
|
The Hospital Anxiety and Depression Scale is a 14-item self-report measure of anxiety and depression symptoms that was designed for the hospital environment.
Each subscale has 7-items answered on a 4-point scale ranging from 0 to 3, yielding a maximum possible score of 21 for each subscale.
Higher scores indicate worse symptoms.
|
Pretreatment, immediately after ending treatment, 6-week follow-up
|
|
MINI Montreal International Neuropsychiatric Interview v. 7.0.2 (MINI)
時間枠：Pretreatment, immediately after ending treatment, 6-week follow-up
|
The MINI is a brief (~15 minutes) structured psychodiagnostic interview for assessing DSM-5 disorders.
|
Pretreatment, immediately after ending treatment, 6-week follow-up
|
|
Dyadic Relationship Scale (DRS)
時間枠：Pretreatment, immediately after ending treatment, 6-week follow-up
|
The Dyadic Relationship Scale is a self-report survey measuring dyadic strain and positive dyadic interaction specific to patient's health.
There is a 10-item patient-version and 11-item caregiver version.
Dyadic strain subscale scores range from 0-12 (patient version) and 0-15 (caregiver version).
Positive dyadic interaction subscale scores range from 0-18.
Higher scores on each of these scales indicate higher levels of strain and positive interaction, respectively.
|
Pretreatment, immediately after ending treatment, 6-week follow-up
|
|
Significant Other's Responses to Trauma Scale (SORTS)
時間枠：Pretreatment, immediately after ending treatment, 6-week follow-up
|
The Significant Other's Responses to Trauma Scale is a 14-item self-report measure assessing frequency & intensity of caregiver PTSD accommodation behaviors.
Total scores can range from 0-112 with higher scores indicating greater accommodation.
|
Pretreatment, immediately after ending treatment, 6-week follow-up
|
協力者と研究者
ここでは、この調査に関係する人々や組織を見つけることができます。
捜査官
- 主任研究者：Sarah Stoycos, PhD、University of Southern California, Keck School of Medicine
研究記録日
これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。
主要日程の研究
研究開始 (推定)
2026年8月1日
一次修了 (推定)
2028年12月31日
研究の完了 (推定)
2029年2月28日
試験登録日
最初に提出
2026年6月3日
QC基準を満たした最初の提出物
2026年6月14日
最初の投稿 (実際)
2026年6月18日
学習記録の更新
投稿された最後の更新 (実際)
2026年6月18日
QC基準を満たした最後の更新が送信されました
2026年6月14日
最終確認日
2026年6月1日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
- HS-25-00383
- 1K23MH141296-01 (米国 NIH グラント/契約)
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
はい
IPD プランの説明
De-identified demographic and raw quantitative data will be deposited into the NIMH Data Archive (NDA).
All data will be de-identified prior to receipt by the repository.
Data will be de-identified pursuant to the HIPAA Privacy Rule, 45 CFR § 164.514(b).
A brief study protocol will also be submitted to NDA and will be made freely available.
IPD 共有時間枠
Data will be deposited starting 18 months after the award begins and will be deposited every six months thereafter following the usual NDA data submission dates.
Data generated from this project will be made available as soon as possible, and no later than the time of publication or the end of the funding period, whichever comes first.
The duration of preservation and sharing of the data is controlled by the NDA; NDA currently has no process for deleting or retiring datasets, and thus far no data has been removed to our knowledge.
IPD 共有アクセス基準
To request access to the data, researchers can use the standard processes at NDA; the NDA Data Access Committee will review requests and decide which requests to grant.
The standard NDA access process allows access for one year and is renewable thereafter.
IPD 共有サポート情報タイプ
- STUDY_PROTOCOL
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
いいえ
米国FDA規制機器製品の研究
いいえ
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。